Cost–utility and price threshold analysis of sacituzumab tirumotecan versus single-agent chemotherapy for previously treated metastatic triple-negative breast cancer in China
Frontiers in Public Health · 23.04.2026 · 14
DOI: 10.3389/fpubh.2026.1786762 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, online erschienen am 23.04.2026. Verfasst von Liman Huo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antineoplastic Agents. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Sacituzumab tirumotecan (Sac-TMT) has demonstrated survival benefits over chemotherapy in patients with previously treated metastatic triple-negative breast cancer (mTNBC). However, its economic value under different payment contexts in China remains uncertain.
Methods
A state-transition (Markov) model was used to estimate lifetime costs and quality-adjusted life-years (QALYs) for Sac-TMT versus single-agent chemotherapy in second-line and later-line mTNBC. Clinical efficacy was derived from a phase III randomized trial, with survival extrapolated using parametric models. Cost–utility and price threshold analyses were conducted using willingness-to-pay (WTP) thresholds defined as three times the per-capita gross domestic product (GDP) at the national level and in economically underdeveloped regions. Scenarios incorporating patient assistance programs were also evaluated.
Results
Sac-TMT increased QALYs but incurred substantially higher costs, resulting in incremental cost-effectiveness ratios exceeding both national and regional WTP thresholds at the current list price. To achieve cost-effectiveness, the price of Sac-TMT would need to be reduced to 48.3% of the current list price under the national WTP threshold and to 34.9% under the regional threshold. Although patient assistance programs increased the acceptable price range, Sac-TMT remained unlikely to be cost-effective at the list price. The reimbursed price following the 2025 national health insurance negotiation was markedly below these thresholds, suggesting improved economic value under current reimbursement conditions.
Conclusion
Sac-TMT is unlikely to be cost-effective at its current list price for previously treated mTNBC in China. Substantial price reductions and reimbursement strategies may improve its economic value, particularly in economically underdeveloped regions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
- Department of Ultrasound, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
- Office of Academic Affairs, The Third Hospital of Hebei Medical University, Shijiazhuang, China.
Zitieren
APA
Huo, L., Feng, X., Liang, P., Wang, Y., Peng, H., Guo, R., Feng, R., & Zheng, Y. (2026). Cost–utility and price threshold analysis of sacituzumab tirumotecan versus single-agent chemotherapy for previously treated metastatic triple-negative breast cancer in China. Frontiers in Public Health, 14. https://doi.org/10.3389/fpubh.2026.1786762
Vancouver
Huo L, Feng X, Liang P, Wang Y, Peng H, Guo R, et al. Cost–utility and price threshold analysis of sacituzumab tirumotecan versus single-agent chemotherapy for previously treated metastatic triple-negative breast cancer in China. Frontiers in Public Health. 2026;14. doi:10.3389/fpubh.2026.1786762
BibTeX
@article{Huo2026,
author = {Huo, Liman and Feng, Xiaojie and Liang, Ping and Wang, Yajing and Peng, Haoyang and Guo, Rong and Feng, Rui and Zheng, Ying},
title = {Cost–utility and price threshold analysis of sacituzumab tirumotecan versus single-agent chemotherapy for previously treated metastatic triple-negative breast cancer in China},
journal = {Frontiers in Public Health},
year = {2026},
volume = {14},
doi = {10.3389/fpubh.2026.1786762}
}
EUVIMED